이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study

2019년 1월 30일 업데이트: Pfizer

TREATMENT PATTERNS AND OUTCOMES IN PATIENTS TREATED WITH BENEFIX OR REFACTO/REFACTO AF - A SWEDISH COHORT STUDY

The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF in Sweden

연구 개요

상태

완전한

정황

상세 설명

The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, as well as the related direct treatment costs in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF, and in subgroups (e.g. level of severity) at the MHC in Sweden.

The study population will consist of all patients diagnosed with haemophilia (D66.9 (haemophilia A) D67.9 (haemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the MHR since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product (Benefix August 27 1997, ReFacto April 13 1999, ReFacto AF July 1 2009). Diseased individuals are included. Information on drugs picked up at the pharmacy is available in the Prescribed Drug Register from 2005.

연구 유형

관찰

등록 (실제)

86

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

확률 샘플

연구 인구

The study population will consist of all patients diagnosed with hemophilia (D66.9 (hemophilia A) D67.9 (hemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the Malmö Hemophilia Register since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product (Benefix August 27 1997, ReFacto April 13 1999, ReFacto AF July 1 2009). Diseased individuals are included.

설명

Inclusion Criteria:

  • The study population will consist of all patients diagnosed with hemophilia (D66.9 (hemophilia A) D67.9 (hemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the Malmö Hemophilia Register since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product

Exclusion Criteria:

  • No exclusion criteria in this study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
Patients with Haemophilia A
Patients in The MHR diagnosed with Haemophilia A
Patients with Haemophilia B
Patients in The MHR diagnosed with Haemophilia B

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Age of Participants at Disease Diagnosis
기간: At disease diagnosis within 11 years before the study start date (Day 1)
At disease diagnosis within 11 years before the study start date (Day 1)
Age of Participants at Start of Treatment With Benefix or Refacto
기간: At start of treatment with Benefix/Refacto within 11 years before the study start date (Day 1)
At start of treatment with Benefix/Refacto within 11 years before the study start date (Day 1)
Age of Participants at Start of Replacement Treatment
기간: At start of replacement treatment within 11 years before the study start date (Day 1)
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor. Replacement treatment could be given prophylactically or to stop the bleed and/or to stop it from becoming more severe.
At start of replacement treatment within 11 years before the study start date (Day 1)
Average Prescribed Dose Per Infusion for Factor VIII and Factor IX Concentrates
기간: For the duration of 11 years before the study start date (Day 1)
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX). Data was measured in international units (IU) for factor VIII and factor IX concentrates.
For the duration of 11 years before the study start date (Day 1)
Average Prescribed Dose Per Kilogram Bodyweight for Factor VIII and Factor IX Concentrates
기간: For the duration of 11 years before the study start date (Day 1)
The average dose per kilogram body weight of factor VIII and IX was defined as a set of two derived variables from the MHR based on information on prescribed replacement treatment (Benefix or Refacto/Refacto AF): prescribed dose per infusion divided by registered body weight (all participants) and prescribed dose per week (prescribed dose per infusion multiplied by registered number of infusions per week) divided by registered body weight (only participants on prophylaxis).
For the duration of 11 years before the study start date (Day 1)
Percentage of Participants on Prophylactic Treatment
기간: For the duration of 11 years before the study start date (Day 1)
Prophylactic treatment was defined as administration of drug regularly to reduce the insufficiency of coagulation factor to prevent bleeding to occur.
For the duration of 11 years before the study start date (Day 1)
Average Prescribed Frequency of Infusions Per Week Dispensed for Haemophilia A or B Participants With Prophylaxis
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)
Average Prescribed Annual Dose of Factor VIII and IX Concentrates for Participants on Prophylaxis
기간: For the duration of 11 years before the study start date (Day 1)
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX). Prescribed annual dose of factor concentrate was derived from the MHR registration of prescribed annual dose of factor concentrate.
For the duration of 11 years before the study start date (Day 1)
Average Prescribed Annual Dose of Factor VIII and IX Concentrates Per Kilogram Bodyweight for Participants on Prophylaxis
기간: For the duration of 11 years before the study start date (Day 1)
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX). Prescribed annual dose of factor concentrate per kilogram body weight was derived from the MHR registration of prescribed annual dose of factor concentrate and the registered body weight.
For the duration of 11 years before the study start date (Day 1)
Average Annual Registered Consumption of Factor VIII and IX Concentrates
기간: For the duration of 11 years before the study start date (Day 1)
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX). Average annual registered consumption of factor VIII and IX concentrates was defined as MHR registered participant's reports on factor concentrate consumption during calendar year.
For the duration of 11 years before the study start date (Day 1)
Number of Participants With Consumption of Factor VIII, Factor IX, Factor rVIIa and/or aPCC Concentrate
기간: For the duration of 11 years before the study start date (Day 1)
Participants who develop inhibitors to factor VIII or IX concentrates were treated with bypassing agents in the form of activated prothrombin complex concentrate (aPCC) which was measured in units (U) and/or recombinant factor VIIa (rFVIIa) measured in micrograms (mcg).
For the duration of 11 years before the study start date (Day 1)
Percentage of Time on Refacto or Benefix
기간: For the duration of 11 years before the study start date (Day 1)
Percentage of time (in days) on Refacto/Refacto AF or Benefix was calculated as total number of days when participant was prescribed Refacto/Refacto AF or Benefix over the total number of days on any replacement treatment. Total number of days on any replacement treatment was derived from date of start of replacement treatment according to MHR and August 31, 2015 or date of death, whichever was earliest.
For the duration of 11 years before the study start date (Day 1)
Average Use of Factor Concentrate Per Surgery Event at Hospital for Invasive Procedures
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)
Average Factor Concentrate Use at Hospital for Invasive Procedures
기간: For the duration of 11 years before the study start date (Day 1)
Average factor concentrate use was calculated as percentage of total annual use of factor concentrates (in IU) at hospital for invasive procedures.
For the duration of 11 years before the study start date (Day 1)
Average Annual Number of Filled Prescriptions of Factor Concentrate
기간: For a duration of 3 years (for up to 11 years before the study start Day 1)
Data at end of every year was based on the number of filled prescriptions during the last 3 years.
For a duration of 3 years (for up to 11 years before the study start Day 1)
Average Annual Number of Dispensed Units of Factor Concentrate
기간: For a duration of 3 years (for up to 11 years before the study start Day 1)
To assess annual consumption of factor concentrates, calculations were based on prescription date as start of use and the day before the next prescription as the last date of use of the factor concentrates retrieved. The annual number of dispensed units of factor concentrate were then summed up of all dispensed units of factor concentrate with periods within the calendar year plus estimates of average daily use periods extending over two years. Data at end of every year was based on the number of dispensed units of factor concentrate during the last 3 years.
For a duration of 3 years (for up to 11 years before the study start Day 1)
Average Number of Units of Benefix or Refacto
기간: For the duration of 11 years before the study start date (Day 1)
Data from the National Board of Health and Welfare (NBHW) had information on all filled prescriptions from July 1, 2005-last date of observation (August 31, 2015). Derived variable calculated as total number of units of filled prescriptions of Refacto/Refacto AF and Benefix over the total units of all factor VIII concentrates and factor IX concentrates, respectively. Total number of units were derived from the date of start of NBHW to last available observation or date of death, whichever was earliest.
For the duration of 11 years before the study start date (Day 1)
Total Number of Bleeds
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)
Number of Joint Bleed, Muscle Bleeds and Other Bleed Events in Participants
기간: For the duration of 11 years before the study start date (Day 1)
Joint bleeds included traumatic and spontaneous joint bleeds, muscle bleeds included traumatic and spontaneous soft tissue bleeds and other bleed events included intracranial bleed, gastrointestinal bleed and urinary tract bleed.
For the duration of 11 years before the study start date (Day 1)
Gilbert Joint Score
기간: Data analyzed on study start Day 1 for the duration of 4 years (2005 to 2009)
Gilbert joint score was an instrument to measure joint health in the domain of body structure and function (i.e. impairment), of the joints most commonly affected by bleeding in haemophilia - knees, ankles, elbows. Total score ranged from 0-100, evaluating ankle, knee and elbow, where "0" indicated normal joint function, "100" indicated worst joint function, where higher values indicated more impairment in joints.
Data analyzed on study start Day 1 for the duration of 4 years (2005 to 2009)
Haemophilia Joint Health Score
기간: Data analyzed on study start Day 1 for the duration of 6 years (2009 to 2015)
Haemophilia Joint Health Score (HJHS) was used to assess joint damage in participants with haemophilia. Total score ranges from 0 to 124, where, 0 indicates normal function, and 124 indicates worst joint function, higher values indicated more damage in joints.
Data analyzed on study start Day 1 for the duration of 6 years (2009 to 2015)
Percentage of Participants With Surgeries
기간: For the duration of 11 years before the study start date (Day 1)
Percentage of participants who had any type of surgery (arthrodesis, surgery on foot, nose, elbow, hand or shoulder, surgery on hip, surgery on knee, tooth extraction, venous port or any other) during the data observation period were reported.
For the duration of 11 years before the study start date (Day 1)
Average Relative Dose Intensity of Factor Concentrate Dispensed for Haemophilia A or B Participants on Prophylaxis Based on Dispensed Volume of Units
기간: For the duration of 11 years before the study start date (Day 1)
Relative dose intensity based on dispensed volume of units was calculated using annual dispensed volume of factor concentrate per participant divided by annual prescribed dose per participant. Data was analysed for 2 categories separately: children/adolescents and adults.
For the duration of 11 years before the study start date (Day 1)
Average Cost of Replacement Treatment (Benefix or Refacto/Refacto AF) Related to Bleed Event
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)

2차 결과 측정

결과 측정
기간
Average Annual Cost of Prescribed Factor Concentrate and Dispensed Replacement Treatment
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)
Average Cost of Replacement Treatment Related to Invasive Procedures
기간: For the duration of 11 years before the study start date (Day 1)
For the duration of 11 years before the study start date (Day 1)

기타 결과 측정

결과 측정
측정값 설명
기간
Average Annual Cost of Replacement Treatment Related to Invasive Procedures
기간: Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
Average Cost for Replacement Treatment Related to Invasive Procedures
기간: Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
The average cost for replacement treatment related to invasive procedures was derived from the percentage of total costs for dispensed replacement therapy and calculated as: cost of factor concentrate used for invasive procedures/ total cost of factor concentrate.
Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Pfizer

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 1월 11일

기본 완료 (실제)

2017년 12월 31일

연구 완료 (실제)

2017년 12월 31일

연구 등록 날짜

최초 제출

2015년 12월 16일

QC 기준을 충족하는 최초 제출

2016년 4월 11일

처음 게시됨 (추정)

2016년 4월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2019년 5월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2019년 1월 30일

마지막으로 확인됨

2019년 1월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • B1821054

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

혈우병 A에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Portugal

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다